CN109010298A - A kind of melbine glipizide compound and preparation method thereof - Google Patents
A kind of melbine glipizide compound and preparation method thereof Download PDFInfo
- Publication number
- CN109010298A CN109010298A CN201811009420.0A CN201811009420A CN109010298A CN 109010298 A CN109010298 A CN 109010298A CN 201811009420 A CN201811009420 A CN 201811009420A CN 109010298 A CN109010298 A CN 109010298A
- Authority
- CN
- China
- Prior art keywords
- glipizide
- metformin hydrochloride
- magnesium stearate
- clad
- label
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Diabetic melbine glipizide composite tablet and preparation method thereof is treated the present invention relates to a kind of, belongs to pharmaceutical technology field.The technical scheme is that a kind of Metformin hydrochloride Glipizide composite tablet composition, is made of label and clad, the magnesium stearate in label containing Metformin hydrochloride and Nei Jia, clad contains Glipizide.Invention both improves the stability of drug release, and improve the compressibility of product and the uniformity of dosage units problem of Glipizide, the drug provided for clinic.
Description
Technical field
Diabetic melbine glipizide composite tablet and preparation method thereof is treated the present invention relates to a kind of, is belonged to
Pharmaceutical technology field.
Background technique
Diabetes are a kind of metabolic diseases characterized by hyperglycemia, because defect of insulin secretion or its biological effect by
Caused by damage or two kinds of factors have concurrently.Long term hyperglycemia easily causes the chronic damage of body tissue, especially kidney, heart, blood vessel etc.
Evil, has been considered as " killer " of the third-largest harm human health after tumour, cardiovascular and cerebrovascular disease.
Metformin hydrochloride Glipizide compound preparation is a kind of improvement type 2 diabetic patient blood glucose listed in recent years
Drug, two kinds of mechanism of drug action complementations greatly improve patient medication compliance while improving convenience.
Metformin hydrochloride is white, needle-shaped crystals, is mostly led because of its acicular crystal containing Metformin hydrochloride component tablet
The decline of tablet compressibility is caused, tabletting " capping " phenomenon easily occurs, conventional settling mode has omnipotent pulverization process, control pellet moisture
It causes mobility of particle to decline because moisture improves in higher level, raising ambient humidity, reduction tablet press machine speed etc., but easily, mentions
High ambient humidity brings highly energy-consuming, reduces tablet press machine speed and causes production efficiency low, and above-mentioned measure often less effective.Together
When because in product Metformin hydrochloride component recrystallization polymerization, cause hardness increase, drug release rate decline, cause product quality drop
Low, smashed Metformin hydrochloride specific surface area increases, recrystallization polymerization aggravation.The U.S. is the same as kind reference preparation
(glipizide and metformin hydrochloride tablet, TEVA PHARMACEUTICALS USA) label is flat
About 130 newton of equal hardness, storage requirement requires to be 20-25 DEG C, we have discovered that it is in acceleration (40 DEG C/75%RH) condition
Under, also there is rate of releasing drug to slow down phenomenon, in China vast in territory, remains that original is ground because being difficult in storage or transportational process
The storage temperature range of formulation requirements, the drug release risk of instability for eventually resulting in preparation occur.
Technical solution
Goal of the invention: overcoming the shortcomings of prior art, using 130 newton of reference preparation average hardness as lowest hardness requirement,
Under the premise of guaranteeing product dissolution rate, solve the problems, such as the capping in current tableting processes, and during storage it is unstable
Problem provides a kind of Metformin hydrochloride Glipizide compound preparation of stable, the suitable industrialized production of Release Performance.
Technical solution:
Applicant is found surprisingly that the unconventional use of magnesium stearate, i.e. breakthrough magnesium stearate is used as the routine of lubricant
The range for measuring 0.25-0.5% (W/W), improves drug release in Metformin hydrochloride Glipizide composite tablet well
Stability and product compressibility.Principle is inferred as the dosage that appropriateness increases magnesium stearate, can obstruct Metformin hydrochloride particle
Between reunion so that prevent further recrystallization process.Unconventional dosage uses in a certain range, does not cause to press
Property decline problem, blocking effect is dominant instead, surprisingly improves this product compressibility.Simultaneously in prescription Glipizide ingredient use with
It is added by spraying after film coating pre-mix dose homogenate, ensure that the content uniformity of Glipizide, finally obtained release and stablize, can press
The qualified products that property is good, content uniformity is good.
The technical scheme is that a kind of Metformin hydrochloride Glipizide composite tablet composition, by label and packet
Coating forms, and the magnesium stearate containing Metformin hydrochloride and Nei Jia in label, clad contains Glipizide.
Metformin hydrochloride Glipizide composite tablet composition of the present invention, in the composition of unit dose, label
Containing Metformin hydrochloride 500mg, magnesium stearate (interior to add) 25-40mg, microcrystalline cellulose 65-80mg, cornstarch 53mg,
Croscarmellose sodium 22.7mg, povidone 12.3mg, magnesium stearate (additional) 7mg；Clad contains Glipizide
The film coating pre-mix dose 21mg of 2.5mg, model 85F18422.
Preferably, Metformin hydrochloride Glipizide composite tablet composition of the present invention, the composition of unit dose
In, it is made of label and clad, in the composition of unit dose, label contains Metformin hydrochloride 500mg, magnesium stearate
(interior to add) 27-33mg, microcrystalline cellulose 75-78mg, cornstarch 53mg, croscarmellose sodium 22.7mg, povidone
12.3mg, magnesium stearate (additional) 7mg；Clad contains Glipizide 2.5mg, the film-coating premixing of model 85F18422
Agent 21mg.
The film coating pre-mix dose of model 85F18422 of the present invention, from Shanghai Colorcon Coating Technology Co., Ltd
Purchase.
The preparation method of Metformin hydrochloride Glipizide composite tablet of the present invention, comprising the following steps:
Step 1: the Metformin hydrochloride of recipe quantity is placed in wet mixing pelletizer with the magnesium stearate of interior dosage and mixes
Uniformly；
Step 2: step 1 gained mixture and the microcrystalline cellulose of Core formulation amount, cornstarch, cross-linked carboxymethyl is fine
The plain sodium of dimension, which is placed in wet mixing pelletizer, to be uniformly mixed；
Step 3: the povidone of recipe quantity is formulated as 7.5% aqueous solution, is added in step 2 gained mixture, wet process system
(additional) mixing of recipe quantity magnesium stearate is added in grain, fluidized bed drying to pellet moisture 2.5-4.5%, Fastgranulatemachine whole grain
Uniformly, tabletting, machine 250,000 tablets hs of speed, aimed hardness are not less than 130 Ns；
Step 4: preparing film coating pre-mix dose solution described in prescription, (recipe quantity film coating pre-mix dose and purified water are uniform
Mix, concentration is 12% (W/W)), recipe quantity Glipizide is slowly added thereto, colloid mill is dispersed with stirring uniformly, is obtained
Film coating pre-mix dose solution containing active constituent coats outer layer drug containing coatings.
The preparation method of Metformin hydrochloride Glipizide composite tablet of the present invention, the cladding outer layer drug containing coating
Layer is completed in a manner of being atomized and spraying into.
The utility model has the advantages that
The implementation of technical solution of the present invention, the preparation of Metformin hydrochloride and magnesium stearate mixture, both improves drug
The stability of release, and the compressibility of product is improved, the drug provided for clinic.
Because main ingredient Glipizide specification is small, prescription accounting only 0.36% is interior plus be not easy to be uniformly mixed, the present invention use and
The mode that coating powder atomization sprays into is added, and ensure that the content uniformity of Glipizide.
Embodiment
By preparation method described in prescription described in table 1 and technical solution, embodiment 1-5 and reference examples are prepared respectively
1-2 product each 1000.
1 embodiment of table and reference examples composition
Note 1 is adhesive solvent, is removed in drying process of pelletizing.
Note 2 is coating solvent, is removed in coating process.
Reference examples 4,3 prescription of reference implementation example, specific as follows:
Label: Metformin hydrochloride 500g, Glipizide 2.5g, interior stiffened fatty acid magnesium 32.5g, microcrystalline cellulose 72.5g,
Cornstarch 53g, croscarmellose sodium 22.7g, povidone 12.3g, additional magnesium stearate 7.0g；Film-coating premixing
Agent 85F18422 21g, prepares 1000 as follows
Step 1: the Metformin hydrochloride of recipe quantity is placed in wet mixing pelletizer with the magnesium stearate of interior dosage and mixes
Uniformly；
Step 2: by Glipizide, microcrystalline cellulose, the cornstarch, friendship of step 1 gained mixture and Core formulation amount
Connection sodium carboxymethylcellulose, which is placed in wet mixing pelletizer, to be uniformly mixed；
Step 3: the povidone of recipe quantity is formulated as 7.5% aqueous solution, is added in step 2 gained mixture, wet process system
(additional) mixing of recipe quantity magnesium stearate is added in grain, fluidized bed drying to pellet moisture 2.5-4.5%, Fastgranulatemachine whole grain
Uniformly, tabletting, machine 250,000 tablets hs of speed, aimed hardness are not less than 130 Ns；
Step 4: preparing film coating pre-mix dose solution described in prescription, (recipe quantity film coating pre-mix dose and purified water are uniform
Mix, concentration is 12% (W/W)), colloid mill, which is dispersed with stirring, uniformly obtains the film coating pre-mix dose containing active constituent
Solution, atomization spray into coating.
The dissolution test of tablet prepared by test example 1. embodiment 1-5 and reference examples 1-3:
Leaching condition: PH6.8 medium, 50 turns of paddle method (Chinese Pharmacopoeia 0,931 second method of version general rule in 2015) test 0 respectively
The dissolution rate at it and accelerated test (40 DEG C of ± 2 DEG C/RH75 ± 5%) the 3rd the end of month, 6 the end of month samples, referring to United States Pharmacopeia USP40-
NF35 standard, Metformin hydrochloride and 45min Glipizide accumulate the amount of dissolution when counting 30min, and data are shown in Table 2.
Situation is dissolved out under the conditions of 2 embodiment of table and reference examples accelerated test
Test example 2
Embodiment 1-5 and reference examples 1-4 content, uniformity of dosage units and the evaluation of plain piece hardness
Measuring method: referring to United States Pharmacopeia USP40-NF35 standard, plaid matching column levels of pyrazine and uniformity of dosage units, hydrochloric acid two
First biguanides content is measured evaluation, while being monitored evaluation to plain piece hardness.
3 content of table, uniformity of dosage units and the evaluation of tabletting hardness
Table 2,3 statistics indicate that, embodiment 1-5 is with magnesium stearate weight ratio compared to reference examples 1-4, Metformin hydrochloride
When 100:5.0-100:8.0, Metformin hydrochloride and Glipizide release stability are superior to reference examples 1-2 and reference system
Agent, when weight ratio is 100:5.6-100:7.4, Metformin hydrochloride and Glipizide release stability are optimal.
Comparing compressibility can solve to produce when Metformin hydrochloride and magnesium stearate weight ratio are 100:5.0-100:8.0
Product compressibility problem, reaches that hardness is consistent or more excellent with reference preparation, and magnesium stearate dosage continues growing, and compressibility is then in now
Drop trend.
Glipizide is added with the mode of coating, solves it and contain by 3 data of table explanation, preparation method of the present invention
Measure the exceeded problem of the uniformity.
To sum up, Metformin hydrochloride and magnesium stearate weight ratio are 100:5.0-100:8.0, comparative example and control
Example has obtained the quality product that release is stablized, compressibility is good, has reached goal of the invention.
Tablet friability is the index for reflecting tablet antivibration wear resistant ability, and friability numerical value is smaller, shows the wear-resisting of tablet
Performance is better.3 data of table illustrate that the friability of tablet prepared by 1-5 of the embodiment of the present invention is significantly better than the number of reference examples 1,2,4
Value.I.e. in the case where guaranteeing dissolution rate, the wearability of product of the embodiment of the present invention is better than reference examples, is conducive to that product is kept to exist
It is still firm in handling process.
Claims (4)
1. a kind of Metformin hydrochloride Glipizide composite tablet composition, which is characterized in that be made of label and clad, piece
Magnesium stearate in core containing Metformin hydrochloride and Nei Jia, clad contain Glipizide.
2. the Metformin hydrochloride Glipizide composite tablet composition according to claim 1, which is characterized in that unit
In the composition of dosage, label contains Metformin hydrochloride 500mg, magnesium stearate (interior to add) 25-40mg, microcrystalline cellulose 65-
80mg, cornstarch 53mg, croscarmellose sodium 22.7mg, povidone 12.3mg, magnesium stearate (additional) 7mg；Packet
Coating contains Glipizide 2.5mg, the film coating pre-mix dose 21mg of model 85F18422.
3. the Metformin hydrochloride Glipizide composite tablet composition according to claim 1, which is characterized in that unit
It in the composition of dosage, is made of label and clad, in the composition of unit dose, label contains Metformin hydrochloride
500mg, magnesium stearate (interior to add) 27-33mg, microcrystalline cellulose 75-78mg, cornstarch 53mg, croscarmellose sodium
22.7mg, povidone 12.3mg, magnesium stearate (additional) 7mg；Clad contains Glipizide 2.5mg, model 85F18422
Film coating pre-mix dose 21mg.
4. the preparation method of the Metformin hydrochloride Glipizide composite tablet composition, feature described in claim 1 exist
In, comprising the following steps:
Step 1: the Metformin hydrochloride of recipe quantity is placed in wet mixing pelletizer with the magnesium stearate of interior dosage and is uniformly mixed；
Step 2: by microcrystalline cellulose, the cornstarch, cross-linked carboxymethyl cellulose of step 1 gained mixture and Core formulation amount
Sodium is placed in wet mixing pelletizer and is uniformly mixed；
Step 3: the povidone of recipe quantity is formulated as 7.5% aqueous solution, is added in step 2 gained mixture, wet granulation, stream
It is dry to pellet moisture 2.5-4.5% to change bed, Fastgranulatemachine whole grain, addition recipe quantity magnesium stearate is (additional) to be uniformly mixed, pressure
Piece；
Step 4: recipe quantity film coating pre-mix dose is uniformly mixed with purified water, the coating solution that compound concentration is 12%, by prescription
Amount Glipizide is slowly added thereto, and colloid mill is dispersed with stirring that uniformly to obtain the film coating pre-mix dose containing active constituent molten
Liquid, the mode for being atomized penetrating complete cladding outer layer drug containing coatings.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811009420.0A CN109010298B (en) | 2018-08-31 | 2018-08-31 | Metformin and glipizide compound composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811009420.0A CN109010298B (en) | 2018-08-31 | 2018-08-31 | Metformin and glipizide compound composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109010298A true CN109010298A (en) | 2018-12-18 |
| CN109010298B CN109010298B (en) | 2020-10-27 |
Family
ID=64625999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811009420.0A Active CN109010298B (en) | 2018-08-31 | 2018-08-31 | Metformin and glipizide compound composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109010298B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110215437A (en) * | 2019-07-18 | 2019-09-10 | 北京中惠药业有限公司 | A kind of metformin hydrochloride tablet and preparation method thereof |
| CN113616613A (en) * | 2021-08-30 | 2021-11-09 | 河南合智医药科技有限公司 | Metformin-glipizide compound tablet for treating diabetes and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002080887A2 (en) * | 2001-04-10 | 2002-10-17 | Sun Pharmaceutical Industries Limited | Timed pulse release composition |
| CN1617728A (en) * | 2001-12-17 | 2005-05-18 | 布里斯托尔-迈尔斯斯奎布公司 | Antidiabetic formulation and method |
| CN101810628A (en) * | 2010-04-13 | 2010-08-25 | 北京四环科宝制药有限公司 | Melbine glipizide tablet and preparation method thereof |
| CN103494816A (en) * | 2013-09-29 | 2014-01-08 | 迪沙药业集团有限公司 | Pharmaceutical composition for treating diabetes mellitus |
| CN104473894A (en) * | 2014-12-18 | 2015-04-01 | 浙江华海药业股份有限公司 | Pioglitazone hydrochloride medicine-loading coating preparation and preparation method thereof |
| WO2015071889A1 (en) * | 2013-11-18 | 2015-05-21 | Ranbaxy Laboratories Limited | Oral compositions of saxagliptin |
| CN104644633A (en) * | 2015-01-30 | 2015-05-27 | 华润赛科药业有限责任公司 | Preparation method of high-stability amlodipine atorvastatin calcium tablet |
| CN105250231A (en) * | 2015-11-02 | 2016-01-20 | 北京泰德制药股份有限公司 | Drug combination containing etoricoxib and preparation method thereof |
-
2018
- 2018-08-31 CN CN201811009420.0A patent/CN109010298B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002080887A2 (en) * | 2001-04-10 | 2002-10-17 | Sun Pharmaceutical Industries Limited | Timed pulse release composition |
| CN1617728A (en) * | 2001-12-17 | 2005-05-18 | 布里斯托尔-迈尔斯斯奎布公司 | Antidiabetic formulation and method |
| CN101810628A (en) * | 2010-04-13 | 2010-08-25 | 北京四环科宝制药有限公司 | Melbine glipizide tablet and preparation method thereof |
| CN103494816A (en) * | 2013-09-29 | 2014-01-08 | 迪沙药业集团有限公司 | Pharmaceutical composition for treating diabetes mellitus |
| WO2015071889A1 (en) * | 2013-11-18 | 2015-05-21 | Ranbaxy Laboratories Limited | Oral compositions of saxagliptin |
| CN104473894A (en) * | 2014-12-18 | 2015-04-01 | 浙江华海药业股份有限公司 | Pioglitazone hydrochloride medicine-loading coating preparation and preparation method thereof |
| CN104644633A (en) * | 2015-01-30 | 2015-05-27 | 华润赛科药业有限责任公司 | Preparation method of high-stability amlodipine atorvastatin calcium tablet |
| CN105250231A (en) * | 2015-11-02 | 2016-01-20 | 北京泰德制药股份有限公司 | Drug combination containing etoricoxib and preparation method thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110215437A (en) * | 2019-07-18 | 2019-09-10 | 北京中惠药业有限公司 | A kind of metformin hydrochloride tablet and preparation method thereof |
| CN110215437B (en) * | 2019-07-18 | 2021-10-08 | 北京中惠药业有限公司 | Metformin hydrochloride tablet and preparation method thereof |
| CN113616613A (en) * | 2021-08-30 | 2021-11-09 | 河南合智医药科技有限公司 | Metformin-glipizide compound tablet for treating diabetes and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109010298B (en) | 2020-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101579325B (en) | Metformin hydrochloride controlled-release tablet and preparation method thereof | |
| CN103479592B (en) | Metformin hydrochloride sustained release tablets and preparation method thereof | |
| CN105213346B (en) | A kind of pharmaceutical composition and preparation method thereof containing cinacalcet hydrochloride | |
| CN102218042A (en) | Sustained release tablet of quetiapine fumarate composition and preparation method of sustained release tablet | |
| CN107184559A (en) | A kind of diabecron sustained-release tablet and preparation method thereof | |
| CN106727404A (en) | Diabecron sustained-release tablet and preparation method thereof | |
| CN109010298A (en) | A kind of melbine glipizide compound and preparation method thereof | |
| CN106265641A (en) | A kind of pharmaceutical composition containing vildagliptin and metformin and preparation method thereof | |
| CN105233300A (en) | Stable vildagliptin composition and preparation method thereof | |
| CN104873473A (en) | Potassium chloride sustained-release tablet and preparation method thereof | |
| CN106924237B (en) | It is a kind of containing En Gelie is net and the pharmaceutical composition of Metformin hydrochloride | |
| CN103565774B (en) | A kind of Glipizide controlled release composition and preparation method thereof | |
| CN111557920A (en) | Lipoic acid-containing tablet and preparation method thereof | |
| CN110585155A (en) | Gliclazide tablet (II) and preparation method thereof | |
| CN103705515B (en) | The preparation method of the pharmaceutical composition that contains Repaglinide and Metformin hydrochloride | |
| CN113616613A (en) | Metformin-glipizide compound tablet for treating diabetes and preparation method thereof | |
| CN112494485B (en) | Saxagliptin and metformin hydrochloride sustained-release tablet | |
| CN105030717A (en) | Moxifloxacin hydrochloride film-coated tablet and preparation method thereof | |
| CN107441051B (en) | Propafenone hydrochloride micro-tablet and preparation method thereof | |
| CN105663131B (en) | A kind of Repaglinide metformin tablet medicament composition and preparation method thereof | |
| CN104367562A (en) | Pramipexole dihydrochloride slow-release tablets and preparation method thereof | |
| CN108420807B (en) | Metformin hydrochloride pharmaceutical composition preparation and preparation method thereof | |
| CN105193758A (en) | Gliclazide sustained release tablets and preparation method thereof | |
| CN111939135A (en) | Sustained-release tablet of metformin hydrochloride medicament and preparation method thereof | |
| CN103494816B (en) | A kind of pharmaceutical composition for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200902 Address after: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Applicant after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Applicant after: Dijia Pharmaceutical Group Co.,Ltd. Address before: 264205 South Qingdao Road-1-4, Weihai Economic and Technological Development Zone, Weihai City, Shandong Province Applicant before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Applicant before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210622 Address after: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: Dijia Pharmaceutical Group Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Metformin glipizide compound composition and preparation method thereof Effective date of registration: 20211025 Granted publication date: 20201027 Pledgee: Bank of China Limited Weihai Branch Pledgor: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Registration number: Y2021980010533 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |